An innovative, effective and tolerable epigenetic cancer therapy for orphan cancer indication

Important results from the project

The overall goal of the project has been to generate a drug candidate with verified market potential, and which is technically mature for testing in the clinical phase in the intended indication, and which can be commercialized. The project has sought external capital and succeeded in attracting investors for seed funding which is an indication of the value of the results for the project. The funding allows for continued work prior to testing in the clinical phase for which additional funding will be needed.

Expected long term effects

A company has been formed by the project partners and seed funding has been secured. During the course of the project, new knowledge has emerged for expanded opportunities to reach the market as there is an opportunity to include a veterinary medical indication. The patent and regulatory strategy has been thoroughly investigated and the conditions have been created for the creation of intellectual property rights, which will be owned by the joint company.

Approach and implementation

The project has followed the standard for a small molecule project from early phase to nomination of clinical candidate. In this phase there are generally a number of risks, which have been known from the beginning and which have been addressed with adequate risk mitigation strategies. Drug design and development requires multi-parameter optimisation, which for this particular target has been laborious. Still, the project has resulted in invaluable knowledge and that supports the further development towards the clinic.